{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T10:52:03Z","timestamp":1791629523803,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"DOI":"10.7759\/cureus.101053","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:29:02Z","timestamp":1767857342000},"source":"Crossref","is-referenced-by-count":4,"title":["Recent Advances in Pharmacological Management of Autism: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Pallavi","family":"Abhilasha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01183-1","article-title":"An update on psychopharmacological treatment of autism spectrum disorder","volume":"19","author":"Aishworiya R","year":"2022","unstructured":"Aishworiya R, Valica T, Hagerman R, Restrepo B. An update on psychopharmacological treatment of autism spectrum disorder. Neurotherapeutics. 2022, 19:248-62. 10.1007\/s13311-022-01183-1","journal-title":"Neurotherapeutics"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01916-2","article-title":"New advances in the diagnosis and treatment of autism spectrum disorders","volume":"29","author":"Qin L","year":"2024","unstructured":"Qin L, Wang H, Ning W, Cui M, Wang Q. New advances in the diagnosis and treatment of autism spectrum disorders. Eur J Med Res. 2024, 29:322. 10.1186\/s40001-024-01916-2","journal-title":"Eur J Med Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-020-00370-1","article-title":"Autism spectrum disorder at the crossroad between genes and environment: contributions, convergences, and interactions in ASD developmental pathophysiology","volume":"11","author":"Cheroni C","year":"2020","unstructured":"Cheroni C, Caporale N, Testa G. Autism spectrum disorder at the crossroad between genes and environment: contributions, convergences, and interactions in ASD developmental pathophysiology. Mol Autism. 2020, 11:69. 10.1186\/s13229-020-00370-1","journal-title":"Mol Autism"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000718628.09065.1b","article-title":"CE: from the CDC: understanding autism spectrum disorder","volume":"120","author":"Christensen D","year":"2020","unstructured":"Christensen D, Zubler J. CE: from the CDC: understanding autism spectrum disorder. Am J Nurs. 2020, 120:30-7. 10.1097\/01.NAJ.0000718628.09065.1b","journal-title":"Am J Nurs"},{"key":"ref5","article-title":"Pharmacological therapies for autism spectrum disorder: a review","volume":"40","author":"LeClerc S","year":"2015","unstructured":"LeClerc S, Easley D. Pharmacological therapies for autism spectrum disorder: a review. P T. 2015, 40:389-97.","journal-title":"P T"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108564","article-title":"Retracing our steps: a review on autism research in children, its limitation and impending pharmacological interventions","volume":"253","author":"Salloum-Asfar S","year":"2024","unstructured":"Salloum-Asfar S, Zawia N, Abdulla SA. Retracing our steps: a review on autism research in children, its limitation and impending pharmacological interventions. Pharmacol Ther. 2024, 253:108564. 10.1016\/j.pharmthera.2023.108564","journal-title":"Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1087054719866255","article-title":"Pharmacotherapy of ADHD in adults with autism spectrum disorder: effectiveness and side effects","volume":"24","author":"Muit JJ","year":"2020","unstructured":"Muit JJ, Bothof N, Kan CC. Pharmacotherapy of ADHD in adults with autism spectrum disorder: effectiveness and side effects. J Atten Disord. 2020, 24:215-25. 10.1177\/1087054719866255","journal-title":"J Atten Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003495.pub2","article-title":"Intravenous secretin for autism spectrum disorder","author":"Williams KW","year":"2005","unstructured":"Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005, CD003495. 10.1002\/14651858.CD003495.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apa.70204","article-title":"Bumetanide treatment in 15 children with autism: a randomised waitlist-control study","volume":"114","author":"Fernell E","year":"2025","unstructured":"Fernell E, Landberg S, Miniscalco C, et al.. Bumetanide treatment in 15 children with autism: a randomised waitlist-control study. Acta Paediatr. 2025, 114:2985-92. 10.1111\/apa.70204","journal-title":"Acta Paediatr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2021.08.009","article-title":"Prediction of behavioral improvement through resting-state electroencephalography and clinical severity in a randomized controlled trial testing bumetanide in autism spectrum disorder","volume":"8","author":"Juarez-Martinez EL","year":"2023","unstructured":"Juarez-Martinez EL, Sprengers JJ, Cristian G, et al.. Prediction of behavioral improvement through resting-state electroencephalography and clinical severity in a randomized controlled trial testing bumetanide in autism spectrum disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023, 8:251-61. 10.1016\/j.bpsc.2021.08.009","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.701729","article-title":"A phase II randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of arbaclofen administered for the treatment of social function in children and adolescents with autism spectrum disorders: study protocol for AIMS-2-TRIALS-CT1","volume":"12","author":"Parellada M","year":"2021","unstructured":"Parellada M, San Jos\u00e9 C\u00e1ceres A, Palmer M, et al.. A phase II randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of arbaclofen administered for the treatment of social function in children and adolescents with autism spectrum disorders: study protocol for AIMS-2-TRIALS-CT1. Front Psychiatry. 2021, 12:701729. 10.3389\/fpsyt.2021.701729","journal-title":"Front Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2017.12.007","article-title":"Antipurinergic therapy for autism-an in-depth review","volume":"43","author":"Naviaux RK","year":"2018","unstructured":"Naviaux RK. Antipurinergic therapy for autism-an in-depth review. Mitochondrion. 2018, 43:1-15. 10.1016\/j.mito.2017.12.007","journal-title":"Mitochondrion"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102603","article-title":"Vasopressin as possible treatment option in autism spectrum disorder","volume":"11","author":"L\u00e1szl\u00f3 K","year":"2023","unstructured":"L\u00e1szl\u00f3 K, V\u00f6r\u00f6s D, Correia P, Fazekas CL, T\u00f6r\u00f6k B, Plang\u00e1r I, Zelena D. Vasopressin as possible treatment option in autism spectrum disorder. Biomedicines. 2023, 11:2603. 10.3390\/biomedicines11102603","journal-title":"Biomedicines"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.792490","article-title":"Alteration of gut microbiota: new strategy for treating autism spectrum disorder","volume":"10","author":"Liu J","year":"2022","unstructured":"Liu J, Gao Z, Liu C, Liu T, Gao J, Cai Y, Fan X. Alteration of gut microbiota: new strategy for treating autism spectrum disorder. Front Cell Dev Biol. 2022, 10:792490. 10.3389\/fcell.2022.792490","journal-title":"Front Cell Dev Biol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04666-3","article-title":"A bibliometric analysis of global research status and trends in neuromodulation techniques in the treatment of autism spectrum disorder","volume":"23","author":"Xiao L","year":"2023","unstructured":"Xiao L, Huo X, Wang Y, et al.. A bibliometric analysis of global research status and trends in neuromodulation techniques in the treatment of autism spectrum disorder. BMC Psychiatry. 2023, 23:183. 10.1186\/s12888-023-04666-3","journal-title":"BMC Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2020.100832","article-title":"Transcranial magnetic stimulation in autism spectrum disorders: neuropathological underpinnings and clinical correlations","volume":"35","author":"Casanova MF","year":"2020","unstructured":"Casanova MF, Sokhadze EM, Casanova EL, Li X. Transcranial magnetic stimulation in autism spectrum disorders: neuropathological underpinnings and clinical correlations. Semin Pediatr Neurol. 2020, 35:100832. 10.1016\/j.spen.2020.100832","journal-title":"Semin Pediatr Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13020345","article-title":"EEG features in autism spectrum disorder: a retrospective analysis in a cohort of preschool children","volume":"13","author":"Santarone ME","year":"2023","unstructured":"Santarone ME, Zambrano S, Zanotta N, et al.. EEG features in autism spectrum disorder: a retrospective analysis in a cohort of preschool children. Brain Sci. 2023, 13:345. 10.3390\/brainsci13020345","journal-title":"Brain Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/392263-recent-advances-in-pharmacological-management-of-autism-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:29:03Z","timestamp":1767857343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/392263-recent-advances-in-pharmacological-management-of-autism-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.101053","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}